Osteoporosetherapie unter Beachtung der Komorbiditäten des Alters

Zusammenfassung

Ältere Patienten mit chronischen Erkrankungen erhalten zu häufig keine adäquate und differenzierte Therapie ihrer Osteoporose. Dabei sollte gerade diesen Patienten eine besondere Aufmerksamkeit zukommen, da deren chronische Erkrankungen wie Herz- und Niereninsuffizienz und Diabetes mellitus Typ II den Knochenstoffwechsel negativ beeinflussen und die Frakturrate signifikant erhöhen. Daher ist es unerlässlich, vor Therapieeinleitung eine gezielte laborchemische Untersuchung durchzuführen, um den gestörten Knochenstoffwechsels zu beurteilen und geeignete Therapieformen abzuleiten. Eine interdisziplinäre Behandlung ist angezeigt.

Abstract

In older patients with chronic illnesses, such as heart or renal failure, diabetes mellitus and hypertension, we should pay particular attention to the possibility of an undiagnosed osteoporosis. The aforementioned illnesses, due to their pathophysiological impairment of the bone mineral density, are associated with an increased fracture rate. Studies show that these patients frequently do not receive an adequate therapy for osteoporosis. It is critical, therefore, before beginning a specific therapy for osteoporosis, to undertake a differentiated biochemical investigation as to the cause of the illness, and to define the relevant deficiencies and surpluses present, in order to provide an adequate therapy.

Schlüsselwörter

Osteoporose - Knochenstoffwechsel - Komorbidität

Key words

Osteoporosis - Bone remodeling - Comorbidity

• Literatur

• 1 Bassgen K, Westphal T, Haar P. et al. Population-based prospective study on the incidence of osteoporosis-associated fractures in a German population of 200, 413 inhabitants. Journal of public health 2013; 35: 255-261
• 2 Binkley N, Krueger D, Buehring B. What’s in a name revisited. Osteoporosis international 2013; 24: 2955-2959
• 3 Jacob L, Breuer J, Kostev K. Prevalence of chronic diseases among older patients in German general practices. GMS e-journal 2016; 14: Doc03
• 4 Cummings SR, Eastell R. Risk and Prevention of Fracture in Patients With Major Medical Illnesses, Journal of bone and mineral research. The official journal of the American Society for Bone and Mineral Research 2016; 31: 2069-2072
• 5 Dede AD, Tournis S, Dontas I. et al. Type 2 diabetes mellitus and fracture risk. Metabolism: clinical and experimental 2014; 63: 1480-1490
• 6 Shanbhogue VV, Mitchell DM, Rosen CJ. et al. Type 2 diabetes and the skeleton. The lancet. Diabetes & endocrinology 2016; 4: 159-173
• 7 Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocrine reviews 2015; 36: 194-213
• 8 Larina VN, Raspopova TN. Bone Metabolism and Mineral Density in Chronic Heart Failure. Kardiologiia 2016; 56: 39-46
• 9 Xing W, Lv X, Gao W. et al. Bone mineral density in patients with chronic heart failure. Clinical interventions in aging 2018; 13: 343-353
• 10 Pimentel A, Urena-Torres P, Zillikens MC. et al. Fractures in patients with CKD-diagnosis, treatment, and prevention. Kidney international 2017; 92: 1343-1355
• 11 Kazama JJ. Chronic kidney disease and fragility fracture. Clinical and experimental nephrology 2017; 21: 46-52
• 12 Fohtung RB, Brown DL, Koh WJH etb al. Bone Mineral Density and Risk of Heart Failure in Older Adults. Journal of the American Heart Association; 2017 6.
• 13 Lyons KJ, Majumdar SR, Ezekowitz JA. The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure, Circulation. Heart failure 2011; 4: 419-424
• 14 Shane E, Mancini D, Aaronson K. et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. The American journal of medicine 1997; 103: 197-207
• 15 Terrovitis J, Zotos P, Kaldara E. et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. European journal of heart failure 2012; 14: 326-332
• 16 Sennerby U, Melhus H, Gedeborg R. et al. Cardiovascular diseases and risk of hip fracture. JAMA 2009; 302: 1666-1673
• 17 Majumdar SR, Ezekowitz JA, Lix LM. et al. Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures. The Journal of clinical endocrinology and metabolism 2012; 97: 1179-1186
• 18 Kraus D, Wanner C. Epidemiologie chronischer Nierenerkrankungen – werden es immer mehr Patienten?. Deutsche Medizinische Wochenschrift 2017; 142: 1276-1281
• 19 Ketteler M, Block GA, Evenepoel P. et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. Annals of internal medicine 2018; 168: 422-430
• 20 Wagner M, Wanner C, Schich M. et al. Patient’s and physician’s awareness of kidney disease in coronary heart disease patients – a cross-sectional analysis of the German subset of the EUROASPIRE IV survey. BMC nephrology 2017; 18: 321
• 21 Jehle PM, Jehle D, Jentsch M. Management of renal hyperparathyroidism. Osteologie 2017; 26: 135-138
• 22 Aluoch AO, Jessee R, Habal H. et al. Heart failure as a risk factor for osteoporosis and fractures. Current osteoporosis reports 2012; 10: 258-269
• 23 Dachverband für Osteologie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern. Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e. V.. https://www.dv-osteologie.org/dvo_leitlinien/dvo-leitlinie-2017
• 24 Miyaoka D, Imanishi Y, Ohara M. et al. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporosis international 2019; 30: 241-249
• 25 Lehmann G, Pfeil A, Wolf G. Effects of teriparatide on bone histology in a patient with adynamic bone disease and vertebral fractures. Osteologie 2017; 26: 153-156
• 26 Cummings SR, Cosman F, Lewiecki EM. et al. Goal-Directed Treatment for Osteoporosis. Journal of bone and mineral research 2017; 32: 3-10
• 27 Hadji P, Claus V, Ziller V. et al. GRAND. Osteoporosis international 2012; 23: 223-231